Cargando…

Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii

BACKGROUND: Vitamin B(12) is a widely used compound in the feed and food, healthcare and medical industries that can only be produced by fermentation because of the complexity of its chemical synthesis. Besides, the use of Generally Recognized as Safe (GRAS) and Qualified Presumption of Safety (QPS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvillo, Álvaro, Pellicer, Teresa, Carnicer, Marc, Planas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912679/
https://www.ncbi.nlm.nih.gov/pubmed/36759843
http://dx.doi.org/10.1186/s12934-023-02029-x
_version_ 1784885256360296448
author Calvillo, Álvaro
Pellicer, Teresa
Carnicer, Marc
Planas, Antoni
author_facet Calvillo, Álvaro
Pellicer, Teresa
Carnicer, Marc
Planas, Antoni
author_sort Calvillo, Álvaro
collection PubMed
description BACKGROUND: Vitamin B(12) is a widely used compound in the feed and food, healthcare and medical industries that can only be produced by fermentation because of the complexity of its chemical synthesis. Besides, the use of Generally Recognized as Safe (GRAS) and Qualified Presumption of Safety (QPS) microorganisms, like Propionibacterium freudenreichii, especially non-GMO wild-type producers, are becoming an interesting alternative in markets where many final consumers have high health and ecological awareness. In this study, the production of vitamin B(12) using the Propionibacterium freudenreichii NBRC 12391 wild-type strain was characterized and optimized in shake flasks before assessing several scale-up strategies. RESULTS: Initial results established that: (i) agitation during the early stages of the culture had an inhibitory effect on the volumetric production, (ii) 5,6-dimethylbenzimidazole (DMBI) addition was necessary for vitamin B(12) production, and (iii) kinetics of vitamin B(12) accumulation were dependent on the induction time when DMBI was added. When scaling up in a bioreactor, both batch and fed-batch bioprocesses proved unsuitable for obtaining high volumetric productivities mainly due to carbon source limitation and propionic acid inhibition, respectively. To overcome these drawbacks, an anaerobic single-phase continuous bioprocess strategy was developed. This culture strategy was maintained stable during more than 5 residence times in two independent cultures, resulting in 5.7-fold increase in terms of volumetric productivity compared to other scale-up strategies. CONCLUSION: Overall, compared to previously reported strategies aimed to reduce propionic acid inhibition, a less complex anaerobic single-phase continuous and more scalable bioprocess was achieved. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02029-x.
format Online
Article
Text
id pubmed-9912679
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99126792023-02-11 Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii Calvillo, Álvaro Pellicer, Teresa Carnicer, Marc Planas, Antoni Microb Cell Fact Research BACKGROUND: Vitamin B(12) is a widely used compound in the feed and food, healthcare and medical industries that can only be produced by fermentation because of the complexity of its chemical synthesis. Besides, the use of Generally Recognized as Safe (GRAS) and Qualified Presumption of Safety (QPS) microorganisms, like Propionibacterium freudenreichii, especially non-GMO wild-type producers, are becoming an interesting alternative in markets where many final consumers have high health and ecological awareness. In this study, the production of vitamin B(12) using the Propionibacterium freudenreichii NBRC 12391 wild-type strain was characterized and optimized in shake flasks before assessing several scale-up strategies. RESULTS: Initial results established that: (i) agitation during the early stages of the culture had an inhibitory effect on the volumetric production, (ii) 5,6-dimethylbenzimidazole (DMBI) addition was necessary for vitamin B(12) production, and (iii) kinetics of vitamin B(12) accumulation were dependent on the induction time when DMBI was added. When scaling up in a bioreactor, both batch and fed-batch bioprocesses proved unsuitable for obtaining high volumetric productivities mainly due to carbon source limitation and propionic acid inhibition, respectively. To overcome these drawbacks, an anaerobic single-phase continuous bioprocess strategy was developed. This culture strategy was maintained stable during more than 5 residence times in two independent cultures, resulting in 5.7-fold increase in terms of volumetric productivity compared to other scale-up strategies. CONCLUSION: Overall, compared to previously reported strategies aimed to reduce propionic acid inhibition, a less complex anaerobic single-phase continuous and more scalable bioprocess was achieved. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02029-x. BioMed Central 2023-02-09 /pmc/articles/PMC9912679/ /pubmed/36759843 http://dx.doi.org/10.1186/s12934-023-02029-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Calvillo, Álvaro
Pellicer, Teresa
Carnicer, Marc
Planas, Antoni
Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title_full Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title_fullStr Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title_full_unstemmed Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title_short Developing a single-stage continuous process strategy for vitamin B(12) production with Propionibacterium freudenreichii
title_sort developing a single-stage continuous process strategy for vitamin b(12) production with propionibacterium freudenreichii
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912679/
https://www.ncbi.nlm.nih.gov/pubmed/36759843
http://dx.doi.org/10.1186/s12934-023-02029-x
work_keys_str_mv AT calvilloalvaro developingasinglestagecontinuousprocessstrategyforvitaminb12productionwithpropionibacteriumfreudenreichii
AT pellicerteresa developingasinglestagecontinuousprocessstrategyforvitaminb12productionwithpropionibacteriumfreudenreichii
AT carnicermarc developingasinglestagecontinuousprocessstrategyforvitaminb12productionwithpropionibacteriumfreudenreichii
AT planasantoni developingasinglestagecontinuousprocessstrategyforvitaminb12productionwithpropionibacteriumfreudenreichii